The combined PD-L1 immune checkpoint inhibitor (ICI) treatment significantly potentiated the anti-tumor effect of this BNT162b2-based cancer therapeutic strategy, and in some cases, tumor nodules were eliminated by the combined therapy. Here, CD274 is linked to cancer.